Core Insights - CRISPR Therapeutics has achieved significant milestones, including the approval of Casgevy, the first gene-editing therapy using the CRISPR system for rare blood diseases [1] - Despite past achievements, the company has underperformed in the market, but upcoming catalysts in its pipeline have generated investor interest [2] - The company's gene-editing approach has the potential to transform treatment standards in areas with high unmet medical needs, with several promising medicines expected to show progress in the next 12 to 18 months [3] Pipeline Developments - Zugo-cel is a potential treatment for various cancers and autoimmune diseases, designed to overcome limitations of traditional CAR-T therapies by using healthy donor cells instead of patients' own cells [4][5] - Zugo-cel has received the Regenerative Medicine Advanced Therapy designation from the FDA, which aims to expedite the development of treatments with promising early clinical evidence [6] - Other pipeline candidates include CTX310, aimed at lowering bad cholesterol, and SRSD107, a next-generation anticoagulant [6]

As filed with the U.S. Securities and Exchange Commission on December 22, 2025 Registration No. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ____________________________ ESTRELLA IMMUNOPHARMA, INC. (Exact Name of Registrant as Specified in its Charter) ____________________________ (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 6770 86-1 ...

Group 1 - Mustang Bio, Inc. has regained compliance with Nasdaq's minimum stockholders' equity requirement as per Nasdaq Listing Rule 5550(b)(1) [1][2] - The company previously satisfied the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing, thus meeting all Nasdaq Capital Market listing requirements [2] - Mustang Bio is a clinical-stage biopharmaceutical company focused on developing cell therapies for difficult-to-treat cancers, aiming to license or acquire technologies to fund research and development [3] Group 2 - Mustang Bio has partnered with leading medical institutions to advance CAR-T therapies [3] - The company's common stock is registered under the Securities Exchange Act of 1934 and it files periodic reports with the SEC [3]